Valuation: Pegasus Mercantile Inc.

Market Cap 735K 514K 468K 433K 392K 47.99M 770K 5.24M 2.08M 25.93M 1.93M 1.89M 82.14M P/E 2024
-2.5x
P/E 2025 -1.67x
Enterprise Value 825K 576K 525K 486K 440K 53.82M 863K 5.88M 2.33M 29.08M 2.16M 2.12M 92.13M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.18%
Yield 2024 *
-
Yield 2025 -
3 months-45.45%
6 months-45.45%
Current year-40.00%
1 month 0.03
Extreme 0.03
0.03
Current year 0.03
Extreme 0.03
0.15
1 year 0
Extreme 0.005
0.15
3 years 0
Extreme 0.005
0.48
5 years 0
Extreme 0.005
2
10 years 0
Extreme 0.005
14
Manager TitleAgeSince
Chief Executive Officer - 30/11/2017
Director of Finance/CFO 72 01/03/2022
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member - 30/11/2017
Director/Board Member 72 10/04/2019
Director/Board Member - 26/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Chief Executive Officer

1,568,000 11.7281%
09/09/26 Sell

Chief Financial Officer

600,000 4.4878%
31/01/25 Tax

Chief Executive Officer

55,000 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-40.00%-80.00% 280K
-2.86%-6.64%+11.94%+58.44% 175B
-2.43%-7.56%+23.16%+60.68% 138B
-2.01%-5.21%+34.71%+206.84% 97.46B
+0.24%-2.15%-16.34%+10.51% 92.76B
-0.80%-5.70%-9.00%+80.61% 86.99B
-1.65%-5.22%-21.59%+37.67% 82.19B
-0.14%-1.68%+1.22%+56.45% 80.45B
-2.37%-7.18%+41.43%+129.71% 43.87B
-1.81%-4.11%+9.46%+41.55% 42.74B
Average -1.39%-4.17%+3.50%+60.25% 84B
Weighted average by Cap. -1.68%-4.80%+8.24%+73.67%

Financials

2024 2025
Net sales - -
Net income -546K -382K -348K -322K -291K -35.63M -571K -3.89M -1.54M -19.25M -1.43M -1.4M -60.99M -381K -266K -243K -225K -203K -24.87M -399K -2.72M -1.08M -13.44M -999K -978K -42.58M
Net Debt 76.82K 53.68K 48.91K 45.27K 40.95K 5.01M 80.4K 547K 217K 2.71M 201K 197K 8.58M 89.43K 62.49K 56.94K 52.7K 47.67K 5.84M 93.61K 637K 253K 3.15M 234K 230K 9.99M
Projected Income Statement - Annual - Pegasus Mercantile Inc.
Logo Pegasus Mercantile Inc.
Pegasus Mercantile Inc. is a Canada-based prospect generator that provides companies with technology, financial, operational, and management assistance in the market for global wellness products and novel consumer goods and services. The Company is focused on hemp, cannabidiol (CBD), related, functional mushrooms, psilocybin plus other psychedelics, helping companies create sustainable products that elevate their personal health and wellbeing. It is focused on the specific areas of pain, depression and mental illness. By investing in pioneering techniques, such as micro-dosing using organic compounds and synthetic molecules. It is transforming the treatment of chronic pain, psychiatric ailments and depression by pioneering trials of fixed-dose drugs, combining psilocybin, ketamine, and MDMA, embracing the endless possibilities of micro-dosing. It has 100% interest in Shanti Therapeutics Pty Ltd. (Shanti), which is focused on psychedelic MDMA-based drug development research.
Employees
-
  1. Stock Market
  2. Stocks
  3. LOAN.X Stock